PMX 205
- CAS No.
- 514814-49-4
- Chemical Name:
- PMX 205
- Synonyms
- PMX-205;PMX 205 （TFA）;Hydrocinnamate;deamino-Phe-Orn(1)-Pro-D-Cha-Trp-Arg-(1);L-Arginine, N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-, (5→1)-lactam
- CBNumber:
- CB33166333
- Molecular Formula:
- C45H62N10O6
- Molecular Weight:
- 839.04
- MDL Number:
- MFCD31657373
- MOL File:
- 514814-49-4.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Density | 1.38±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Store at -20°C |
| pka | 13.40±0.70(Predicted) |
| Water Solubility | Soluble in 20% ethanol / sterile Water |
| FDA UNII | DC25O3L7KZ |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H319-H315-H335 |
| Precautionary statements | P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362 |
PMX 205 price More Price(35)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 13607 | PMX-205 ≥95% | 514814-49-4 | 500μg | $159 | 2021-12-16 | Buy |
| Cayman Chemical | 13607 | PMX-205 ≥95% | 514814-49-4 | 1mg | $254 | 2021-12-16 | Buy |
| Usbiological | 256287 | PMX 205 Asreported | 514814-49-4 | 1mg | $573 | 2026-06-03 | Buy |
| Biosynth | PVA81449 | PMX 205 | 514814-49-4 | 50mg | $3131.5 | 2026-06-04 | Buy |
| Biosynth | CRB1001059 | PMX 205 | 0.5mg | $165.73 | 2026-06-04 | Buy |
PMX 205 Chemical Properties,Uses,Production
Uses
PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
Definition
ChEBI: PMX-205 is a homodetic cyclic peptide resulting from the formal condensation of the carboxy group of N(2)-(3-phenylpropanoyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine with the 5-amino group of the N(2)-acylornithyl residue. It has a role as an antagonist, an anti-inflammatory agent and a C5a receptor antagonist. It is an azamacrocycle and a homodetic cyclic peptide.
in vivo
PMX 205 (PMX205) is an orally active, selective C5aR antagonist. Animals treated with PMX 205 (1 mg/kg/day, oral) displays a significant extension of survival time and a reduction in end-stage motor scores, as compared with vehicle-treated rats. PMX 205-treated animals also display reduced levels of astroglial proliferation in the lumbar spinal cord. SOD1G93A rats are orally dosed with PMX 205 (1 mg/kg/day) from two time points (days 28 and 70) before the onset of major clinical symptoms. Both treatment groups have a significant extension in survival time compared with untreated rats (p=0.022, day 28; p=0.015, day 70), with no clear differences in outcomes between the two treatment regimens[2]. Tg2576 mice are treated with PMX 205 (PMX205) at 20 μg/mL in the drinking water (n=17) from 12 to 15 mo of age, the time frame at which there is a rapid accumulation of amyloid deposits in these animals. Untreated Tg2576 animals (n=11) are used as controls. After 3 mo, animals treated with PMX 205 show significantly less fibrillar plaque load (thioflavine reactivity) than do untreated animals. In 3×Tg mice, PMX 205 also significantly reduces hyperphosphorylated tau (69%)[3].
storage
Store at -20°C
References
[1] Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment. J Cancer Res Ther. 2016 Apr-Jun;12(2):590-6. DOI:10.4103/0973-1482.146066
[2] Woodruff TM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34. DOI:10.4049/jimmunol.181.12.8727
[3] Fonseca MI, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009 Jul 15;183(2):1375-83. DOI:10.4049/jimmunol.0901005
PMX 205 Preparation Products And Raw materials
Raw materials
Preparation Products
PMX 205 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Creative Peptides | info@creative-peptides.com | United States | 6083 | 56 | |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Nanjing Leon Biological Technology Co., Ltd. | 025-84523390 -127; 17705183659 | sales@njleonbiotech.com | China | 5501 | 55 |
| Hangzhou Peptidego Biotech Co.,Ltd. | 0571-87213919 15967184799 | Eric@peptidego.com | China | 7872 | 58 |
| Fan De(Beijing) Biotechnology Co., Ltd. | 15911056312 | liming@bio-fount.com | China | 9718 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 | sales@sarms4muscle.com | China | 10378 | 58 |
| Binhai gill polypeptide co. LTD | 021-61263389 13524856427 | Joetang@glschina.com | China | 9927 | 58 |
514814-49-4(PMX 205)Related Search:
1of2
